FDA Output, April 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in April 2026. Updated April 30.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in April 2026. Updated April 30.
Three MTI cohort companies seek to add efficiency to various pain points in the practice of collecting medical images.
The treatment of low back pain is beginning to move toward a more stratified, personalized model of care. Scientific and technological advances are creating opportunities for new entrants in the market. Excerpted from our recent feature article.